EirGenix, a contract development and manufacturing organization (CDMO) and a biosimilars maker, has opened a new protein production facility at the Hsinchu Biomedical Park in Zubei, Taiwan, boosting its CDMO capabilities.    In addition to the new facility, the company, together with its parent, Formosa Labs, signed an agreement with Spain’s Oncomatryx Biopharma for the development of new antibody drug conjugates (ADCs).    Since its formation in December 2012, EirGenix has completed more th...